{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:13:30Z","timestamp":1790360010001,"version":"4.1.0"},"reference-count":50,"publisher":"Impact Journals, LLC","issue":"26","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2015,9,9]]},"DOI":"10.18632\/oncotarget.4212","type":"journal-article","created":{"date-parts":[[2015,9,15]],"date-time":"2015-09-15T04:47:30Z","timestamp":1442292450000},"page":"22734-22749","source":"Crossref","is-referenced-by-count":66,"title":["The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia"],"prefix":"10.18632","volume":"6","author":[{"given":"S\u00edlvia","family":"Xargay-Torrent","sequence":"first","affiliation":[{"name":"Experimental Therapeutics in Lymphoid Malignancies Group, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"L\u00f3pez-Guerra","sequence":"additional","affiliation":[{"name":"Experimental Therapeutics in Lymphoid Malignancies Group, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"},{"name":"Hematopathology Unit, Department of Pathology, Hospital Clinic, University of Barcelona, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laia","family":"Rosich","sequence":"additional","affiliation":[{"name":"Experimental Therapeutics in Lymphoid Malignancies Group, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnau","family":"Montraveta","sequence":"additional","affiliation":[{"name":"Experimental Therapeutics in Lymphoid Malignancies Group, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocabed","family":"Rold\u00e1n","sequence":"additional","affiliation":[{"name":"Experimental Therapeutics in Lymphoid Malignancies Group, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanina","family":"Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Experimental Therapeutics in Lymphoid Malignancies Group, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neus","family":"Villamor","sequence":"additional","affiliation":[{"name":"Hematopathology Unit, Department of Pathology, Hospital Clinic, University of Barcelona, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Aymerich","sequence":"additional","affiliation":[{"name":"Hematopathology Unit, Department of Pathology, Hospital Clinic, University of Barcelona, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandraiah","family":"Lagisetti","sequence":"additional","affiliation":[{"name":"Center for Chemical Biology, Biosciences Division, SRI International, Menlo Park, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"Webb","sequence":"additional","affiliation":[{"name":"Center for Chemical Biology, Biosciences Division, SRI International, Menlo Park, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"L\u00f3pez-Ot\u00edn","sequence":"additional","affiliation":[{"name":"Departamento de Bioqu\u00edmica y Biolog\u00eda Molecular, Universidad de Oviedo - IUOPA, Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Campo","sequence":"additional","affiliation":[{"name":"Hematopathology Unit, Department of Pathology, Hospital Clinic, University of Barcelona, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolors","family":"Colomer","sequence":"additional","affiliation":[{"name":"Experimental Therapeutics in Lymphoid Malignancies Group, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"},{"name":"Hematopathology Unit, Department of Pathology, Hospital Clinic, University of Barcelona, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2015,6,8]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1172\/JCI64101","article-title":"Molecular pathogenesis of chronic lymphocytic leukemia","volume":"122","author":"la-Favera","year":"2012","journal-title":"J Clin Invest"},{"key":"2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrc2764","article-title":"From pathogenesis to treatment of chronic lymphocytic leukaemia","volume":"10","author":"Stilgenbauer","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"3","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1200\/JCO.2013.50.8515","article-title":"CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia","volume":"32","author":"Pepper","year":"2014","journal-title":"J Clin Oncol"},{"key":"4","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrclinonc.2010.167","article-title":"Prognostic factors in chronic lymphocytic leukemia-what do we need to know?","volume":"8","author":"Hallek","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"5","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature10113","article-title":"Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia","volume":"475","author":"Juan","year":"2011","journal-title":"Nature"},{"key":"6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/ng.1032","article-title":"Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia","volume":"44","author":"Navarro","year":"2012","journal-title":"Nat Genet"},{"key":"7","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/ng.2584","article-title":"POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia","volume":"45","author":"Puente","year":"2013","journal-title":"Nat Genet"},{"key":"8","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1109016","article-title":"SF3B1 and other novel cancer genes in chronic lymphocytic leukemia","volume":"365","author":"Fernandes","year":"2011","journal-title":"N Engl J Med"},{"key":"9","doi-asserted-by":"crossref","first-page":"6904","DOI":"10.1182\/blood-2011-08-373159","article-title":"Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness","volume":"118","author":"Cerri","year":"2011","journal-title":"Blood"},{"key":"10","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1038\/leu.2012.344","article-title":"Frequent somatic mutations in components of the RNA processing machinery in chronic lymphocytic leukemia","volume":"27","author":"Quesada","year":"2013","journal-title":"Leukemia"},{"key":"11","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/leu.2012.307","article-title":"NOTCH1 and SF3B1 mutations can be added to the hierarchical prognostic classification in chronic lymphocytic leukemia","volume":"27","author":"Rosenquist","year":"2013","journal-title":"Leukemia"},{"key":"12","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1182\/blood-2012-09-458265","article-title":"Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia","volume":"121","author":"Marasca","year":"2013","journal-title":"Blood"},{"key":"13","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMc1204033","article-title":"Chronic lymphocytic leukemia with SF3B1 mutation","volume":"366","author":"Lopez-Otin","year":"2012","journal-title":"N Engl J Med"},{"key":"14","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cell.2013.01.019","article-title":"Evolution and impact of subclonal mutations in chronic lymphocytic leukemia","volume":"152","author":"Shukla","year":"2013","journal-title":"Cell"},{"key":"15","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1158\/0008-5472.CAN-12-2501","article-title":"Targeting the deregulated spliceosome core machinery in cancer cells triggers mTOR blockade and autophagy","volume":"73","author":"Pautier","year":"2013","journal-title":"Cancer Res"},{"key":"16","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nchembio.2007.16","article-title":"Splicing factor SF3b as a target of the antitumor natural product pladienolide","volume":"3","author":"Mizui","year":"2007","journal-title":"Nat Chem Biol"},{"key":"17","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/nchembio.2007.18","article-title":"Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA","volume":"3","author":"Yoshida","year":"2007","journal-title":"Nat Chem Biol"},{"key":"18","doi-asserted-by":"crossref","first-page":"188","DOI":"10.7164\/antibiotics.57.188","article-title":"Pladienolides, new substances from culture of Streptomyces platensis Mer-11107. III.andantitumor activities","volume":"57","author":"Asada","year":"2004","journal-title":"J Antibiot (Tokyo)"},{"key":"19","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.7164\/antibiotics.49.1204","article-title":"New antitumor substances, FR901463, FR901464 and FR901465. II. Activities against experimental tumors in mice and mechanism of action","volume":"49","author":"Shimomura","year":"1996","journal-title":"J Antibiot (Tokyo)"},{"key":"20","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1021\/cb100356k","article-title":"Sudemycins, novel small molecule analogues of FR901464, induce alternative gene splicing","volume":"6","author":"Potter","year":"2011","journal-title":"ACS Chem Biol"},{"key":"21","doi-asserted-by":"crossref","first-page":"6979","DOI":"10.1021\/jm901215m","article-title":"Synthetic mRNA splicing modulator compounds withantitumor activity","volume":"52","author":"Webb","year":"2009","journal-title":"J Med Chem"},{"key":"22","doi-asserted-by":"crossref","first-page":"10033","DOI":"10.1021\/jm401370h","article-title":"Optimization of antitumor modulators of pre-mRNA splicing","volume":"56","author":"Webb","year":"2013","journal-title":"J Med Chem"},{"key":"23","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.cell.2010.07.019","article-title":"An alternative splicing network links cell-cycle control to apoptosis","volume":"142","author":"Silver","year":"2010","journal-title":"Cell"},{"key":"24","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1182\/blood-2010-05-284984","article-title":"The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia","volume":"117","author":"McCoy","year":"2011","journal-title":"Blood"},{"key":"25","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1517\/14728221003598930","article-title":"NF-kappaB as a therapeutic target in chronic lymphocytic leukemia","volume":"14","author":"Colomer","year":"2010","journal-title":"Expert Opin Ther Targets"},{"key":"26","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.gene.2008.07.015","article-title":"Alternative splicing in the NF-kappaB signaling pathway","volume":"423","author":"Gilmore","year":"2008","journal-title":"Gene"},{"key":"27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/2040620714539906","article-title":"Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib","volume":"5","author":"Advani","year":"2014","journal-title":"Ther Adv Hematol"},{"key":"28","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/ni1001-939","article-title":"Direct inhibition of Bruton's tyrosine kinase by IBtk, a Btk-binding protein","volume":"2","author":"Scala","year":"2001","journal-title":"Nat Immunol"},{"key":"29","doi-asserted-by":"crossref","first-page":"4402","DOI":"10.1093\/nar\/gkn413","article-title":"Physical and functional characterization of the genetic locus of IBtk, an inhibitor of Bruton's tyrosine kinase: evidence for three protein isoforms of IBtk","volume":"36","author":"Scala","year":"2008","journal-title":"Nucleic Acids Res"},{"key":"30","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/nrd3823","article-title":"The spliceosome as a target of novel antitumour drugs","volume":"11","author":"Valcarcel","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"31","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrm3525","article-title":"Alternative splicing: a pivotal step between eukaryotic transcription and translation","volume":"14","author":"Munoz","year":"2013","journal-title":"Nat Rev Mol Cell Biol"},{"key":"32","doi-asserted-by":"crossref","first-page":"4627","DOI":"10.1182\/blood-2013-02-427641","article-title":"SF3B1 mutations in chronic lymphocytic leukemia","volume":"121","author":"Wu","year":"2013","journal-title":"Blood"},{"key":"33","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1038\/leu.2013.22","article-title":"Subclonal evolution involving SF3B1 mutations in chronic lymphocytic leukemia","volume":"27","author":"Kipps","year":"2013","journal-title":"Leukemia"},{"key":"34","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1182\/blood-2012-05-429282","article-title":"The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial","volume":"121","author":"Catovsky","year":"2013","journal-title":"Blood"},{"key":"35","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1053\/j.seminhematol.2013.09.005","article-title":"Next-generation sequencing in chronic lymphocytic leukemia","volume":"50","author":"Campo","year":"2013","journal-title":"Semin Hematol"},{"key":"36","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1101\/gad.1284605","article-title":"Mammalian polycomb-mediated repression of Hox genes requires the essential spliceosomal protein Sf3b1","volume":"19","author":"Koseki","year":"2005","journal-title":"Genes Dev"},{"key":"37","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1038\/leu.2013.155","article-title":"Genetic characterization of SF3B1 mutations in single chronic lymphocytic leukemia cells","volume":"27","author":"Jelinek","year":"2013","journal-title":"Leukemia"},{"key":"38","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/leu.2014.318","article-title":"The impact of SF3B1 mutations in CLL on the DNA-damage response","volume":"29","author":"Hullein","year":"2015","journal-title":"Leukemia"},{"key":"39","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1101\/gr.152132.112","article-title":"Transcriptome characterization by RNA sequencing identifies a major molecular and clinical subdivision in chronic lymphocytic leukemia","volume":"24","author":"Djebali","year":"2014","journal-title":"Genome Res"},{"key":"40","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.drudis.2012.07.013","article-title":"The development and application of small molecule modulators of SF3b as therapeutic agents for cancer","volume":"18","author":"Potter","year":"2013","journal-title":"Drug Discov Today"},{"key":"41","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1021\/cb300602j","article-title":"Chemical perturbation of Mcl-1 pre-mRNA splicing to induce apoptosis in cancer cells","volume":"8","author":"Koide","year":"2013","journal-title":"ACS Chem Biol"},{"key":"42","doi-asserted-by":"crossref","first-page":"e1072","DOI":"10.1038\/cddis.2014.40","article-title":"Multiple components of the spliceosome regulate Mcl1 activity in neuroblastoma","volume":"5","author":"Hogarty","year":"2014","journal-title":"Cell Death Dis"},{"key":"43","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1182\/blood-2008-05-157131","article-title":"Mcl-1 expression hasandsignificance in chronic lymphocytic leukemia and is associated with other poor prognostic markers","volume":"112","author":"Fegan","year":"2008","journal-title":"Blood"},{"key":"44","unstructured":"Park, Aicher, Aird, Buonamici, Chan, Eifert, Fekkes, Furman, Gerard, Karr, Keaney, Kunii, Lee, et al. Targeting MCL1-dependent cancers through RNA splicing modulation [abstract]. Proceedings of the 106th Annual Meeting of the American Association for Cancer Research. 2015 Apr 18-22. Philadelphia (PA), AACR. 2015 Abstract nr 2941. 2015."},{"key":"45","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1038\/leu.2013.131","article-title":"Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy","volume":"27","author":"Tisdale","year":"2013","journal-title":"Leukemia"},{"key":"46","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.semcancer.2013.08.011","article-title":"The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies","volume":"24","author":"Gribben","year":"2014","journal-title":"Semin Cancer Biol"},{"key":"47","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0959-8049(14)70582-9","article-title":"SF3B1 mutations induce disease relevant aberrant mRNA splicing in cancer and confer sensitivity to spliceosome inhibition","volume":"50","author":"Kunii","year":"2014","journal-title":"European Journal of Cancer"},{"key":"48","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood-2013-06-511154","article-title":"Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia","volume":"123","author":"MacEwan","year":"2014","journal-title":"Blood"},{"key":"49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.leu.2404457","article-title":"ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia","volume":"21","author":"Rosenquist","year":"2007","journal-title":"Leukemia"},{"key":"50","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1158\/1078-0432.CCR-10-3412","article-title":"Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters","volume":"17","author":"Colomer","year":"2011","journal-title":"Clin Cancer Res"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.4212","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T13:39:52Z","timestamp":1589377192000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.4212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,8]]},"references-count":50,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2015,9,9]]}},"alternative-id":["4212","26068951"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.4212","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,8]]}}}